IP Library Granted Patent US 9,592,242
Granted Patent B2
US 9,592,242 · App. 15/069,584 · Granted Mar 14, 2017

Methods for treating edema in the eye and intraocular implants for use therefor

Inventor: Vernon G. Wong (Menlo Park, CA)
Assignee: Allergan, Inc.
A61K31/573A61F9/0008A61F9/0017A61K9/0048A61K9/0051A61K9/1641A61K9/1647A61K31/56A61K31/715A61K31/765A61K45/06A61K47/34A61L27/54A61F2210/0004A61L2300/222A61L2300/41A61L2300/416A61L2300/604
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,592,242
App. No.
15/069,584
Granted
Mar 14, 2017
Kind
B2
Abstract

Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.

Claims (6)

1. A method for treating edema in an eye of an individual in need thereof, comprising: placing a bioerodible drug delivery system comprising dexamethasone and a bioerodible polymer in an eye of an individual, thereby treating edema of the eye of the individual, wherein the dexamethasone comprises about 60% by weight of the drug delivery system, based on the total weight of the drug delivery system.

2. The method of claim 1 , wherein the biodegradable drug delivery system is placed in the vitreous of the eye.

3. The method of claim 1 , wherein the bioerodible polymer comprises a polylactic acid polyglycolic acid (PLGA) copolymer.

4. The method of claim 1 , wherein the bioerodible drug delivery system delivers the dexamethasone for at least 5 days.

5. The method of claim 1 , wherein the bioerodible drug delivery system delivers the dexamethasone for at least about 3 weeks.

6. The method of claim 1 , wherein the bioerodible drug delivery system delivers the dexamethasone for at least about 12 weeks.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2016
From: WONG, VERNON G.
To: OCULEX PHARMACEUTICALS
Reel/Frame 039177/0083 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2016
From: OCULEX PHARMACEUTICALS, INC.
To: ALLERGAN, INC.
Reel/Frame 039177/0122 →
Continuity (11)
Continuation 14481778 · Sep 9, 2014
Continuation 13871214 · Apr 26, 2013
Continuation 13296957 · Nov 15, 2011
Continuation 11852223 · Sep 7, 2007
Division 11738409 · Apr 20, 2007
Division 11180079 · Jul 11, 2005
Continuation 10744560 · Dec 22, 2003
Continuation 09997094 · Nov 28, 2001
Provisional Application 60250023 · Nov 29, 2000
Provisional Application 60298253 · Jun 12, 2001
Related Publication 20160193230A1 · Jul 7, 2016